Benzinga's Top Pre-Market Losers
Body Central (NASDAQ: BODY) shares fell 25.33% to $11.94 in the pre-market trading. Body Central issued downbeat Q2 earnings forecast.
Infinity Pharmaceuticals (NASDAQ: INFI) dipped 22.55% to $10.75 in the pre-market session. Infinity Pharmaceuticals stopped mid-stage trials of saridegib in chondrosarcoma and myelofibrosis
DSW (NYSE: DSW) shares dropped 8.59% to $53.75 in pre-market trading. DSW reiterated its 2012 forecast. The company's board also authorized a new $100 million stock buyback program.
Steel Dynamics (NASDAQ: STLD) dipped 4.90% to $10.48 in the pre-market session. Steel Dynamics issued downbeat Q2 earnings forecast.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.